Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Nilda Mesa, a director at UNITED THERAPEUTICS (NASDAQ:UTHR), sold 645 shares of common stock on June 24, 2025. The shares were sold at a weighted average price of $289.9926, for a total transaction value of $187,045. The $12.87 billion biotech company currently trades at an attractive P/E ratio of 10.6x and boasts impressive gross profit margins of 89%. InvestingPro analysis suggests the stock is currently undervalued.
The prices for the sale ranged from $289.68 to $290.05. Following the transaction, Mesa directly owns 4,883 shares of UNITED THERAPEUTICS. The company maintains excellent financial health with a perfect Piotroski Score of 9, according to InvestingPro, which offers 12 additional key insights about UTHR in its comprehensive Pro Research Report.
In other recent news, United Therapeutics Corporation announced the completion of enrollment for its phase 3 ADVANCE OUTCOMES study evaluating ralinepag for pulmonary arterial hypertension (PAH). The study includes 728 participants, with top-line data expected in the first half of 2026. Meanwhile, Insmed (NASDAQ:INSM) Incorporated reported positive results from its Phase 2b study of Treprostinil Palmitil Inhalation Powder (TPIP) for PAH, achieving significant reductions in pulmonary vascular resistance and improvements in walk distance. Insmed plans to engage with the FDA for Phase 3 trial design.
Analysts from Leerink Partners have maintained an Outperform rating for United Therapeutics, citing optimism about the phase 3 TETON-2 trial for idiopathic pulmonary fibrosis (IPF). Additionally, TD Cowen reaffirmed a Buy rating on United Therapeutics, highlighting the company’s progress in its product pipeline, including the Tyvaso launch for PH-ILD and the potential of its xenotransplantation platform. In legal developments, a favorable court ruling for Liquidia Technologies (NASDAQ:LQDA) removed immediate barriers to the commercialization of Yutrepia, following a denied injunction request by United Therapeutics. Raymond (NSE:RYMD) James analysts reiterated a Strong Buy rating for Liquidia, emphasizing the positive shift in legal momentum.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.